ArticleDEN open2026
Clinical Significance of Endoscopic Improvement at 6 Months in Patients With Ulcerative Colitis Treated With Ustekinumab: A Retrospective Real-world Analysis.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Ustekinumab (UST), an anti-interleukin-12/23 p40 monoclonal antibody, has emerged as an effective therapeutic option for patients with moderate to severe ulcerative colitis (UC). However, early predictors of long-term treatment response remain unclear. This study aimed to assess whether 6-month endoscopic improvement (EI) predicts sustained clinical remission (CR) in patients with UC treated with UST. Methods: This was a retrospective observational study performed at Kyorin University Hospital. Patients with active UC (Lichtiger Index ≥ 5) who began UST between June 2020 and July 2023 were included. CR was assessed using the LI at weeks 4, 8, 16, and 24. EI at week 24 and sustained CR at week 56 were evaluated. Results: Fifty-seven patients were enrolled, and the CR rate at week 24 was 57.9%. CR at week 4 was significantly associated with CR at week 24 ( Conclusions: EI 6 months after UST initiation was associated with sustained CR at week 56. This finding highlights the importance of early endoscopic assessment in optimizing long-term outcomes in UST-treated UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.